SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------------
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 20, 2004
VAXGEN, INC.
(Exact name of Registrant as Specified in its Charter)
DELAWARE 0-26483 94-3236309
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of organization) incorporation or
Identification Number)
1000 MARINA BLVD., SUITE 200 BRISBANE, CALIFORNIA 94005
(Address of Principal Administrative Offices)
Registrants Telephone Number, Including Area Code: (650) 624-1000
Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related
Auditor Report or Completed Interim Review.
(a) As previously reported in VaxGen, Inc.'s Current Report on Form 8-K
filed May 18, 2004, the Company, with the assistance of independent accounting
and legal advisors, conducted a review of its revenue recognition policy with
respect to certain contracts, most of which are with the National Institute of
Allergy and Infectious Diseases ("NIAID"). The Company was examining whether it
should recognize revenue from these and other similar contracts as it incurs
costs relating to those contracts.
On July 19, 2004, the Company's Audit Committee and Management determined
to adopt a revised revenue recognition policy with respect to the NIAID
contracts and other similar contracts. As a result of the new policy, the
Company intends to restate its financial statements for the years ended December
31, 2003 and 2002. The restatement will require VaxGen's independent auditors to
reaudit financial results for fiscal years 2003, 2002 and 2001. Therefore,
annual and quarterly reports previously filed with the Securities and Exchange
Commission for those periods should not be relied upon.
Both the Company's Audit Committee and the Company's Management have
discussed with the Company's independent registered public accounting firm the
matters discussed in this Current Report on Form 8-K/A.
(b) As previously reported in VaxGen, Inc.'s Current Report on Form 8-K
filed July 22, 2004, on July 20, 2004, the Company's former independent
registered public accounting firm, KPMG LLP ("KPMG"), advised the Company that
because of the Company's announcement regarding restatement, it was KPMG's
understanding that the Management representations previously provided in
connection with the audit of the financial statements for the years ended
December 31, 2003 and 2002 have been withdrawn. Accordingly, KPMG advised the
Company that it could no longer continue to be associated with the Company's
2003 and 2002 financial statements and that their reports on the Company's 2003
and 2002 financial statements should no longer be relied upon. In addition, KPMG
asked VaxGen to inform investors and others that they should not rely on the
2003 and 2002 financial statements and related reports.
An authorized officer of the Company has discussed with KPMG and with the
Company's current independent registered public accounting firm,
PricewaterhouseCoopers LLP, the matters disclosed in this Current Report on Form
8-K/A.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
VaxGen, Inc.
(Registrant)
Dated: November 9, 2004 By: /s/ James M. Cunha
-----------------------------
James M. Cunha
Chief Financial Officer